NFE2L2 and neoplasm: Oncometabolites, such as fumarate and 2-hydroxyglutarate, may promote resistance by upregulating the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, inhibiting the anti-tumor immune response, or promoting angiogenesis (53).